Yi Ni*, Liwei Zhu, Shengwei Wang, Chenghao Liu, Debin Zou Bio LIMS INC, a digital intelligence company for life science labs, Massachusetts, United States *Corresponding author: yi.ni@biolims.net AMP 2025 Date — November, 2025 Location — Boston Abstract Traditional pharmacology and toxicology evaluation faces fundamental limits when dealing with massive heterogeneous data, complex biological mechanisms, and individual variability — only 1 in 5,000 to 1 in 10,000 candidate compounds reaches...

Yi Ni*, Liwei Zhu, Shuai Li Bio LIMS INC, Boston, Massachusetts, United States *Corresponding author: yi.ni@biolims.net arXiv preprint arXiv:2511.08649 November 11, 2025 q-bio.QM · cs.AI Abstract Chimeric antigen receptor T-cell (CAR-T) therapy represents a paradigm shift in cancer treatment, yet development timelines of 8–12 years and clinical attrition rates exceeding 40–60% highlight critical inefficiencies in target selection, safety assessment, and molecular optimization. We present Bio...

October 15–16, 2025 | Philadelphia, USA The American Society of Gene & Cell Therapy (ASGCT) will host the Advancing Cell + Gene Therapies for Cancer meeting, dedicated to breakthroughs and challenges in oncology-focused CGT. Topics include tumor heterogeneity, viral vector & cell therapy combinations, mechanisms of resistance, gene editing optimization, and cross-platform integration. Bio LIMS INC is proud to share that our work “AI agent applications in digital traceability for cell and gene...